A decade of respiratory syncytial virus epidemiology and prophylaxis: Translating evidence into everyday clinical practice

Canadian Respiratory Journal

Volumn 18, Issue 2, 2011, Pages

  Paes, Bosco A ^a   Mitchell, Ian ^b   Banerji, Anna ^c   Lanctôt, Krista L ^d   Langley, Joanne M ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e IWK HEALTH CENTRE   (Canada)

Author keywords

Epidemiology; Prevention; Prophylaxis; Respiratory syncytial virus

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DEXAMETHASONE; MONTELUKAST; MOTAVIZUMAB; PALIVIZUMAB; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RETINOL; RIBAVIRIN;

ABORIGINE; CHILD CARE; CHILD HOSPITALIZATION; CLINICAL PRACTICE; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; EVIDENCE BASED PRACTICE; GESTATIONAL AGE; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; INFECTION COMPLICATION; INFECTION PREVENTION; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; MORBIDITY; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; TRISOMY 21; UNSPECIFIED SIDE EFFECT; VIRAL BRONCHIOLITIS;

EID: 80052752406     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2011/493056     Document Type: Review

References (150)

1. Simoes EA, Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J 2003;22(2 Suppl):S13-20.
2. Anderson LJ, Hierholzer JC, Tsou C, et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 1985;151:626-33.
3. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 1970;23:7-18.
4. Stick S. Pediatric origins of adult lung disease. 1. The contribution of airway development to paediatric and adult lung disease. Thorax 2000;55:587-94.
5. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588-98.
6. Langley JM, Wang EE, Law BJ, et al. Economic evaluation of respiratory syncytial virus infection in Canadian children: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 1997;131:113-7.
7. Health Canada, PPHB. Respiratory Virus Detections/Isolations in Canada. (Accessed on March 1, 2011).
8. Langley JM, LeBlanc JC, Smith B, Wang EE. Increasing incidence of hospitalization for bronchiolitis among Canadian children, 1980-2000. J Infect Dis 2003;188:1764-7.
9. Schanzer DL, Langley JM, Tam TW. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J 2006;25:795-800.
10. Leader S, Kohlase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003;143:S127-32.
11. McLaurin KK, Leader S. Growing impact of RSV hospitalizations among infants in the US, 1997-2002. Abstract 936. Pediatric Academic Societies Annual Meeting. Washington, May 14 to 17, 2005.
12. Arnold SR, Wang EE, Law BJ, et al. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: A review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 1999;18:866-9.
13. Thorburn K. Pre-existing disease is associated with a significantly higher risk of death in severe respiratory syncytial virus infection. Arch Dis Child 2009;94:99-103.
14. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992;121:348-54.
15. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
16. Feltes TF, Cabalka AK, Meissner HC, et al. Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
17. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86.
18. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010;375:1545-55.
19. Panozzo CA, Fowlkes AL, Anderson LJ. Variation in timing of respiratory syncytial virus outbreaks: Lessons from national surveillance. Pediatr Infect Dis J 2007;26:S41-5.
20. Lee JT, Chang LY, Wang LC, et al. Epidemiology of respiratory syncytial virus infection in northern Taiwan, 2001-2005 - seasonality, clinical characteristics, and disease burden. J Microbiol Immunol Infect 2007;40:293-301.
21. Carballal G, Videla C, Sequeira MD, Mistchenko A, Requeijo PV, Arbiza J. Respiratory syncytial virus: Changes in prevalence of subgroups A and B among Argentinian children, 1990-1996. J Med Virol 2000;61:275-9.
22. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infections with subtype. J Pediatr 1997;175:814-20.
23. Wang EE, Law BJ, Robinson JL, et al. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics 1997;99:E9.
24. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991;163:693-8.
25. González PA, Bueno SM, Riedel CA, Kalergis AM. Impairment of T cell immunity by the respiratory syncytial virus: Targeting virulence mechanisms for therapy and prophylaxis. Curr Med Chem 2009;16:4609-25.
26. Welliver RC Sr. The immune response to respiratory syncytial virus infection: Friend or foe? Clin Rev Allergy Immunol 2008;34:163-73.
27. Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;143:S133-41.
28. Willson DF, Landrigan CP, Horn SD, Smout RJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr 2003;143:S142-9.
29. Miedema CJ, Kors AW, Tjon A, Ten WE, Kimpen JL. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in The Netherlands. Pediatr Infect Dis J 2001;20:160-3.
30. Stewart DL, Romero JR, Buysman EK, Fernandes AW, Mahadevia PJ. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention. Curr Med Res Opin 2009;25:2795-804.
31. Ehlken B, Ihorst G, Lippert B, et al. PRIDE Study Group. Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany. Eur J Pediatr 2005;164:607-15.
32. Wert SE. Normal and abnormal structural development of the lung. In: Polin RA, Fox WW, Abman SH, eds. Fetal and Neonatal Physiology, 3rd edn. Philadelphia: Saunders, 2004:783-94.
33. Yeung CY, Hobbs JR. Serum-gamma-G-globulin levels in normal premature, post-mature, and " small-for-dates" newborn babies. Lancet 1968;1:1167-70.
34. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212-9.
35. Law BJ, MacDonald N, Langley J, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? Paediatr Child Health 1998;3:402-4.
36. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003;22:483-90.
37. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003;143:S112-7.
38. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997;99:93-9.
39. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137:865-70.
40. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003;143:S118-26.
41. Liese JG, Grill E, Fischer B, et al. Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:230-6.
42. Holberg CJ, Wright AL, Martinez FD, Morgan WJ, Taussig LM. Child day care, smoking by caregivers, and lower respiratory tract illness in the first 3 years of life. Group Health Medical Associates. Pediatrics 1993;91:885-92.
43. Lanari M, Silvestri M, Rossi GA. Respiratory syncytial virus risk factors in late preterm infants. J Matern Fetal Neonatal Med 2009;22:S102-7.
44. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: A developed country perspective. Respir Med 2002;96:S1-7.
45. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98:708-15.
46. Bulkow LR, Singleton RJ, Karron RA, Harrison LH. Alaska RSV Study Group. Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics 2002;109:210-6.
47. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23:815-20.
48. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. IRIS Study Group. FLIP-2 Study: Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27:788-93.
49. Carbonell-Estrany X, Figueras-Aloy J, Law BJ; Infección Respiratoria Infantil por Virus Respiratorio Sincitial Study Group; Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: Different methodologies yield consistent findings. Pediatr Infect Dis J 2004;23:S193-201.
50. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806-14.
51. Simões EA, Carbonell-Estrany X, Fullarton JR, et al. European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78.
52. Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28:471-80.
53. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400.
54. Altman CA, Englund JA, Demmler G, et al. Respiratory syncytial virus in patients with congenital heart disease: A contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433-8.
55. Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: Postoperative course and outcome. Crit Care Med 1999;27:1974-81.
56. Wilkesmann A, Ammann RA, Schildgen O, et al. DSM RSV Ped Study Group. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 2007;26:485-91.
57. Resch B, Gusenleitner W, Müller WD, Haas J. Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis 2006;25:120-2.
58. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: A novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 2007;120:e1076-81.
59. Kristensen K, Stensballe LG, Bjerre J, et al. Risk factors for respiratory syncytial virus hospitalisation in children with heart disease. Arch Dis Child 2009;94:785-9.
60. Van Ewijk BE, Wolfs TF, Aerts PC, et al. RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 2007;61:398-403.
61. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 1988;113:826-30.
62. Hiatt PW, Grace SC, Kozinetz CA, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103:619-26.
63. Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: Quantitation and duration of shedding. J Pediatr 1976;89:11-5.
64. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986;315:77-81.
65. Craft AW, Reid MM, Gardner PS, et al. Virus infections in children with acute lymphoblastic leukaemia. Arch Dis Child 1979;54:755-9.
66. Milner ME, de la Monte SM, Hutchins GM. Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome. Am J Dis Child 1985;139:1111-4.
67. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009;10:148-53.
68. Evers SE, Rand CG. Morbidity in Canadian Indian and non-Indian children in the first year of life. Can Med Assoc J 1982;126:249-52.
69. Evers SE, Rand CG. Morbidity in Canadian Indian and non-Indian children in the second year. Can J Public Health 1983;74:191-4.
70. Banerji A, Lanctôt KL, Paes BA, et al. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009;28:702-6.
71. Singleton RJ, Bruden D, Bulkow LR, Varney G, Butler JC. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season. Pediatr Infect Dis J 2006;25:1116-22.
72. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children 1980-1996. JAMA 1999;282:1440-6.
73. Banerji A, Greenberg D, White LF, et al. Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: A case-control study. Pediatr Infect Dis J 2009;28:697-701.
74. Moore H, Burgner D, Carville K, Jacoby P, Richmond P, Lehmann D. Diverging trends for lower respiratory infections in non-Aboriginal and Aboriginal children. J Paediatr Child Health 2007;43:451-7.
75. Banerji A, Bell A, Mills EL, et al. Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ 2001;164:1847-50.
76. Reeve CA, Whitehall JS, Buettner PG, Norton R, Reeve DM, Francis F. Predicting respiratory syncytial virus hospitalisation in Australian children. J Paediatr Child Health 2006;42:248-52.
77. Lowther SA, Shay DK, Holman RC, Clarke MJ, Kaufman SF, Anderson LJ. Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatr Infect Dis J 2000;19:11-7.
78. Prais D, Schonfeld T, Amir J; Israeli Respiratory Syncytial Virus Monitoring Group. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: A national survey before palivizumab use. Pediatrics 2003;112:548-52.
79. Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143:S150-6.
80. Simoes EA, Groothuis JR, Carbonell-Estrany X, et al. Palivizumab Long-Term Respiratory Outcomes Study Group. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007;151:34-42,42.e1.
81. Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137-41.
82. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541-5.
83. Pérez-Yarza EG, Moreno A, Lázaro P, Mejías A, Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma: A systematic review of the literature. Pediatr Infect Dis J 2007;26:733-9.
84. Bont L, Steijn M, van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J 2004;23:414-7.
85. Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. Pediatrics 2005;115:1536-46.
86. Hall CB, Douglas RG Jr, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980;141:98-102.
87. Langley JM, LeBlanc JC, Wang EE, et al. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: A Pediatric Investigators Collaborative Network on Infections in Canada Study. Pediatrics 1997;100:943-6.
88. Simon A, Müller A, Khurana K, et al. DSM RSV Paed Study Group. Nosocomial infection: A risk factor for a complicated course in children with respiratory syncytial virus infection - results from a prospective multicenter German surveillance study. Int J Hyg Environ Health 2008;211:241-50.
89. Madge P, Paton JY, McColl JH, Mackie PL. Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet 1992;340:1079-83.
90. Groothuis J, Bauman J, Malinoski F, Eggleston M. Strategies for prevention of RSV nosocomial infection. J Perinatol 2008;28:319-23.
91. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21.
92. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435-48.
93. Schickli JH, Dubovsky F, Tang RS. Challenges in developing a pediatric RSV vaccine. Hum Vaccin 2009;5:582-91.
94. Langley JM, Sales V, McGeer A, et al. A dose-ranging study of a subunit respiratory syncytial virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. Vaccine 2009;27:5913-9.
95. Murata Y. Respiratory syncytial virus vaccine development. Clin Lab Med 2009;29:725-39.
96. Samson L. The Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Paediatr Child Health 2009;14:521-6.
97. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements - modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124:1694-701.
98. Figueras Aloy J, Quero J, Doménech E, et al. Comité de Estándares de la Sociedad Española de Neonatología. [Recommendations for the prevention of respiratory syncytial virus infection.] An Pediatr (Barc) 2005;63:357-62.
99. Rondini G, Macagno F, Barberi I. Raccomandazioni della Societa Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta neonatal 2004;1:1-11.
100. Canadian Paediatric Society. Use of palivizumab in children with congenital heart disease. Paediatr Child Health 2003;8:631-3.
101. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979;121:1193-254.
102. Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lanctôt KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009;12:361-70.
103. Informations sur la disponibilite du synagismc pour la saison 2009-2010. (Accessed on March 1, 2011).
104. Ontario Ministry of Health and Long-Term Care. Synagis. Respiratory Syncytial Virus Prophylaxis for High-Risk Infants Program. 2010. (Accessed on March 1, 2011).
105. Frogel M, Nerwen C, Cohen A, Van Veldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry. J Perinatol 2008;28:511-7.
106. Mitchell I, Paes B, Li A, Lanctôt KL; CARESS Investigators. CARESS: The Candian Registry of Pavilizumab. Paediatr Infect Dis J 2011;Feb 18 (E-pub ahead of print).
107. Giebels K, Marcotte JE, Podoba J, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol 2008;43:169-74.
108. Speer ME, Fernandes CJ, Boron M, Groothuis JR. Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis. Pediatr Infect Dis J 2008;27:559-61.
109. Cohen AH, Boron ML, Dingivan C. A phase IV study of the safety of synagis (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. Poster session presented at the International Conference of the American Thoracic Society. May 20 to 25, 2005, San Diego, California.
110. Giusti R. North American synagis prophylaxis survey. Pediatr Pulmonol 2009;44:96-8.
111. McCormick J, Southern KW. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 2007;92:87-8.
112. Simoes EA. Immunoprophylaxis of respiratory syncytial virus: Global experience. Respir Res 2002;3:S26-33.
113. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003;22:823-7.
114. Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: A " real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 2006;41:1167-74.
115. Paes B, Steele S, Janes M, Pinelli J. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009;25:1585-91.
116. Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ 2009;12:291-300.
117. Nuijten M, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab in children with congenital heart disease in Germany. J Med Econ 2009;12:301-8.
118. Lanctôt KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: A Canadian-based analysis. Curr Med Res Opin 2008;24:3223-37.
119. Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: Results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Ital J Pediatr 2009;35:4.
120. Nuijten MJC, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children. Pharmacoeconomics 2007;25:55-71.
121. Resch B, Gusenleitner W, Nuijten MJ, Lebmeier M, Wittenberg W. Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008;30:749-60.
122. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-11.
123. ElHassan NO, Sorbero MES, Hall CB, Stevens TP, Dick AW. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med 2006;160:1070-6.
124. Wang D, Cummins C, Bayliss S, Sandercock J, Burls A. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: A systematic review and economic evaluation. Health Technol Assess 2008;12:1-86.
125. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: An analysis using observational data. Eur J Health Econ 2010;11:105-15.
126. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;107:419-27.
127. Simpson S, Burls A. A systematic review of the effectiveness and cost-effectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection in infants at high risk of infection. West Midlands Health Technology Assessment Group 2001;1-33. (Accessed on March 1, 2011).
128. Reeve CA, Whitehall JS, Buetnner PG, Norton R, Reeve DM, Francis F. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab. J Paediatr Child Health 2006;42:253-8.
129. Chan PW, Abdel-Latif ME. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Acta Paediatr 2003;92:481-5.
130. Fariña D, Rodriguez SP, Bauer G, et al. Respiratory syncytial virus prophylaxis: Cost-effective analysis in Argentina. Pediatr Infect Dis J 2002;21:287-91.
131. Lofland JH, Touch SM, O'Connor JP, et al. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis. Clin Ther 2000;22:1357-69.
132. Rodriguez SP, Fariña D. Respiratory syncytial virus prophylaxis in a high-risk population in Argentina: A cost-effectiveness analysis. Pediatr Infect Dis J 2008;27:660-1.
133. Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:237-44.
134. Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier. Arch Pediatr Adolesc Med 2000;154:55-61.
135. Vogel AM, McKinlay MJ, Ashton T, et al. Cost-effectiveness of palivizumab in New Zealand. J Paediatr Child Health 2002;38:352-7.
136. Rackham OJ, Thorburn K, Kerr SJ. The potential impact of prophylaxis against bronchiolitis dues to the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005;15:251-5.
137. Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, et al. [The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain.] An Pediatr (Barc) 2006;65:316-24.
138. Krilov LR, Palazzi DL, Fernandes AW, Klein RW, Mahadevia PJ. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States. Value Health 2009;13:77-86.
139. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
140. Bresee JS, Fischer M, Dowell SF, et al. Vitamin A therapy for children with respiratory syncytial virus infection: A multicenter trial in the United States. Pediatr Infect Dis J 1996;15:777-82.
141. Dowell SF, Papic Z, Bresee JS, et al. Treatment of respiratory syncytial virus infection with vitamin A: A randomized, placebo-controlled trial in Santiago, Chile. Pediatr Infect Dis J 1996;15:782-6.
142. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics 2006;118:1774-93.
143. Mitchell I. Treatment of RSV bronchiolitis: Drugs, antibiotics. Paediatr Respir Rev 2009;10:S14-5.
144. Zorc JJ, Hall CB. Bronchiolitis: Recent evidence on diagnosis and management. Pediatrics 2010;125:342-9.
145. Grewal S, Ali S, McConnell DW, Vandermeer B, Klassen TP. A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department. Arc Pediatr Adolesc Med 2009;163:1007-12.
146. Plint AC, Johnson DW, Patel H, et al. Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med 2009;360:2079-89.
147. Carbonell-Estrany X, Simões EA, Dagan R, et al. Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: A noninferiority trial. Pediatrics 2010;125:e35-51.
148. Ramilo O. Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules. Paediatr Respir Rev 2009;10:S23-5.
149. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 2010;107:8800-5.
150. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.